{"id":1002937,"date":"2026-09-11T08:56:18","date_gmt":"2026-09-11T12:56:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/"},"modified":"2026-09-11T08:56:18","modified_gmt":"2026-09-11T12:56:18","slug":"three-nasdaq-cancer-developers-under-10-advance-clinical-programs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/","title":{"rendered":"Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs"},"content":{"rendered":"

\nNeOnc reports Phase 2a brain cancer data as BriaCell and Oncolytics advance breast and colorectal cancer studies
\n<\/h2>\n
\n

DENVER, Sept. 11, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) \u2013 Recent cancer treatment advances span new FDA approvals and ongoing Phase 2 and Phase 3 clinical programs. NeOnc Technologies Holdings (NASDAQ: NTHI), BriaCell Therapeutics (NASDAQ: BCTX) and Oncolytics Biotech (NASDAQ: ONCY) have reported clinical and regulatory developments across brain, breast and colorectal cancer, and all three have recently traded below $10.<\/p>\n

\n NeOnc: Positive Phase 2a brain cancer results<\/strong>\n <\/p>\n

The single-arm, open-label study enrolled 24 patients with recurrent or progressive Grade III or IV IDH1-mutant glioma. In its August 12 announcement<\/u><\/a>, NeOnc reported six-month progression-free survival of 48.9% using RANO 2.0 criteria and Kaplan-Meier estimation, compared with a pre-specified 20% historical benchmark (p = 0.0047). The company reported that the primary endpoint was met under that analysis.<\/p>\n

Median overall survival was 26.09 months. Five patients remained on treatment at the data cutoff, and the company reported no major toxicities, with adverse events predominantly low-grade. Patients self-administered NEO100 intranasally at home four times daily. The companion SEC-filed presentation<\/u><\/a> also reported six-month progression-free survival of 25.8% under the protocol-specified RANO criteria (p = 0.276).<\/p>\n

\n Three FDA designations and next regulatory steps<\/strong>\n <\/p>\n

NEO100 holds FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations<\/u><\/a>. NeOnc plans to request a Type B meeting to seek FDA alignment on a registrational development path<\/u><\/a>. Separately, the FDA’s June 2026 draft guidance<\/u><\/a> describes how one adequate and well-controlled clinical investigation, together with confirmatory evidence, may satisfy the substantial evidence standard for effectiveness. The draft is nonbinding, and NEO100’s future study requirements remain subject to program-specific FDA review.<\/p>\n

\n Second clinical program and delivery platform<\/strong>\n <\/p>\n

NEO212, an oral conjugate of temozolomide and perillyl alcohol, completed Phase 1 dose escalation and established a recommended Phase 2 dose of 610 mg<\/u><\/a>. In its August 10 update<\/u><\/a>, NeOnc said it was incorporating FDA written feedback and meeting discussions into its proposed Phase 2 development strategy. In June, UAE authorities authorized clinical development of both NEO100 and NEO212<\/u><\/a>.<\/p>\n

NEO100 is designed for nose-to-brain delivery along olfactory and trigeminal pathways. NeOnc holds an exclusive USC license covering issued patents and pending applications<\/u><\/a> related to NEO100, NEO212 and other candidates. The company also acquired intellectual property for AI and 3D bioprinting in August 2025<\/u><\/a>, including technology for patient-derived brain-tumor models and preclinical drug screening.<\/p>\n

\n Insider purchases and published analyst coverage<\/strong>\n <\/p>\n

SEC Forms 4 show Chief Executive Officer Amir Heshmatpour purchased 15,000 shares on August 14 and 17<\/u><\/a> and 9,000 on August 18<\/u><\/a>. Director Thomas C. Chen, M.D., Ph.D., reported 36,259 shares purchased on August 14 and 17<\/u><\/a>, plus 12,757 through his IRA on August 18<\/u><\/a>. Chen’s 49,016 shares and Heshmatpour’s 24,000 shares brought their combined purchases after the Phase 2a announcement to 73,016 shares.<\/p>\n

Benzinga’s published rating history records Buy coverage from Alliance Global Partners, BTIG and Maxim Group before NeOnc’s August 12, 2026, Phase 2a readout. Moomoo reported on August 14<\/u><\/a> that Maxim maintained its Buy rating and existing price target. Stock Analysis listed 597,816 shares sold short in NTHI data reviewed September 5, 2026.<\/p>\n

\n BriaCell: Phase 2 survival data and a Phase 3 breast cancer study<\/strong>\n <\/p>\n

BriaCell reported at ASCO 2026<\/u><\/a> that Phase 2 patients receiving the Bria-IMT regimen selected for Phase 3 had median overall survival of 16.6 months. The overall Phase 2 study included 32 heavily pretreated patients with metastatic breast cancer. Its ongoing Phase 3 Bria-ABC study<\/u><\/a> compares Bria-IMT plus an immune checkpoint inhibitor with physician’s choice of treatment. In July, Sunnybrook’s Odette Cancer Centre joined more than 80 active U.S. sites.<\/p>\n

\n Oncolytics: FDA feedback supports the next study stage<\/strong>\n <\/p>\n

Oncolytics is evaluating pelareorep in the randomized Phase 2 REO 033 study<\/u><\/a> for second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer. On August 18<\/u><\/a>, the company reported FDA written feedback that it believes aligns with a potential pivotal Part B expansion. It plans an End-of-Phase meeting to finalize key registration-program elements and would advance the expansion following supportive Part A clinical data.<\/p>\n

\n About 24\/7 Market News<\/strong>\n <\/p>\n

In today’s fast-moving markets, visibility is everything and 24\/7 Market News (24\/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company\u2019s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24\/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com<\/u><\/a> to discuss how 24\/7 can help accelerate your company\u2019s visibility and valuation trajectory.<\/p>\n

This is a paid editorial communication intended for informational purposes only. 24\/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here<\/u><\/a>. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.<\/p>\n

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.<\/p>\n

\n CONTACT:<\/strong>
\n
24\/7 Market News
Editor@247mnn.com<\/u><\/a><\/p>\n

\n Cautionary Note Regarding Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NeOnc reports Phase 2a brain cancer data as BriaCell and Oncolytics advance breast and colorectal cancer studies DENVER, Sept. 11, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) \u2013 Recent cancer treatment advances span new FDA approvals and ongoing Phase 2 and Phase 3 clinical programs. NeOnc Technologies Holdings (NASDAQ: NTHI), BriaCell Therapeutics (NASDAQ: BCTX) and Oncolytics Biotech (NASDAQ: ONCY) have reported clinical and regulatory developments across brain, breast and colorectal cancer, and all three have recently traded below $10. NeOnc: Positive Phase 2a brain cancer results The single-arm, open-label study enrolled 24 patients with recurrent or progressive Grade III or IV IDH1-mutant glioma. In its August 12 announcement, NeOnc reported six-month progression-free survival of 48.9% using RANO 2.0 criteria and Kaplan-Meier estimation, … <\/p>\n

Continue reading “Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1002937","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nThree Nasdaq Cancer Developers Under $10 Advance Clinical Programs - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NeOnc reports Phase 2a brain cancer data as BriaCell and Oncolytics advance breast and colorectal cancer studies DENVER, Sept. 11, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) \u2013 Recent cancer treatment advances span new FDA approvals and ongoing Phase 2 and Phase 3 clinical programs. NeOnc Technologies Holdings (NASDAQ: NTHI), BriaCell Therapeutics (NASDAQ: BCTX) and Oncolytics Biotech (NASDAQ: ONCY) have reported clinical and regulatory developments across brain, breast and colorectal cancer, and all three have recently traded below $10. NeOnc: Positive Phase 2a brain cancer results The single-arm, open-label study enrolled 24 patients with recurrent or progressive Grade III or IV IDH1-mutant glioma. In its August 12 announcement, NeOnc reported six-month progression-free survival of 48.9% using RANO 2.0 criteria and Kaplan-Meier estimation, … Continue reading "Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-11T12:56:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNTEwMSM3ODI4NjM0IzIzMDQzNjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs\",\"datePublished\":\"2026-09-11T12:56:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\\\/\"},\"wordCount\":1017,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNTEwMSM3ODI4NjM0IzIzMDQzNjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\\\/\",\"name\":\"Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNTEwMSM3ODI4NjM0IzIzMDQzNjM=\",\"datePublished\":\"2026-09-11T12:56:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNTEwMSM3ODI4NjM0IzIzMDQzNjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyNTEwMSM3ODI4NjM0IzIzMDQzNjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/","og_locale":"en_US","og_type":"article","og_title":"Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs - Market Newsdesk","og_description":"NeOnc reports Phase 2a brain cancer data as BriaCell and Oncolytics advance breast and colorectal cancer studies DENVER, Sept. 11, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) \u2013 Recent cancer treatment advances span new FDA approvals and ongoing Phase 2 and Phase 3 clinical programs. NeOnc Technologies Holdings (NASDAQ: NTHI), BriaCell Therapeutics (NASDAQ: BCTX) and Oncolytics Biotech (NASDAQ: ONCY) have reported clinical and regulatory developments across brain, breast and colorectal cancer, and all three have recently traded below $10. NeOnc: Positive Phase 2a brain cancer results The single-arm, open-label study enrolled 24 patients with recurrent or progressive Grade III or IV IDH1-mutant glioma. In its August 12 announcement, NeOnc reported six-month progression-free survival of 48.9% using RANO 2.0 criteria and Kaplan-Meier estimation, … Continue reading \"Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-11T12:56:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNTEwMSM3ODI4NjM0IzIzMDQzNjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs","datePublished":"2026-09-11T12:56:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/"},"wordCount":1017,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNTEwMSM3ODI4NjM0IzIzMDQzNjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/","name":"Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNTEwMSM3ODI4NjM0IzIzMDQzNjM=","datePublished":"2026-09-11T12:56:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNTEwMSM3ODI4NjM0IzIzMDQzNjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyNTEwMSM3ODI4NjM0IzIzMDQzNjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/three-nasdaq-cancer-developers-under-10-advance-clinical-programs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1002937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1002937"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1002937\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1002937"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1002937"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1002937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}